Breaking new ground in healthcare data
The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.
Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma. “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).
Pharma, healthcare providers and health ministries have a g...
Source: EyeForPharma - April 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Breaking new ground in healthcare data
The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.
Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma. “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).
Pharma, healthcare providers and health ministries have a g...
Source: EyeForPharma - April 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.
George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,” said Yanco...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.
George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,” said Yanco...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.
George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,” said Yanco...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Up close and personal: The Thomas D ’Hooghe story
While his friends were easing into retirement, Thomas D ’Hooghe MD, 55, was sleepless with excitement at the thought of reinventing himself by jumping from academia to pharma.
It is a move he would recommend to anyone. “It was the best thing I ever did,” says the Vice-President and Head Global Medical Affairs, Fertility at Merck, sitting down with me and sharing his thoughts about passion, purpose, leading people and making a difference. Origins
Working in healthcare was always in his blood. In high school it was never a question; D ’Hooghe would study medicine. It was an ideal way to combine his interests...
Source: EyeForPharma - April 14, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Up close and personal: The Thomas D ’Hooghe story
While his friends were easing into retirement, Thomas D ’Hooghe MD, 55, was sleepless with excitement at the thought of reinventing himself by jumping from academia to pharma.
It is a move he would recommend to anyone. “It was the best thing I ever did,” says the Vice-President and Head Global Medical Affairs, Fertility at Merck, sitting down with me and sharing his thoughts about passion, purpose, leading people and making a difference. Origins
Working in healthcare was always in his blood. In high school it was never a question; D ’Hooghe would study medicine. It was an ideal way to combine his interests...
Source: EyeForPharma - April 14, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Up close and personal: The Thomas D ’Hooghe story
While his friends were easing into retirement, Thomas D ’Hooghe MD, 55, was sleepless with excitement at the thought of reinventing himself by jumping from academia to pharma.
It is a move he would recommend to anyone. “It was the best thing I ever did,” says the Vice-President and Head Global Medical Affairs, Fertility at Merck, sitting down with me and sharing his thoughts about passion, purpose, leading people and making a difference. Origins
Working in healthcare was always in his blood. In high school it was never a question; D ’Hooghe would study medicine. It was an ideal way to combine his interests...
Source: EyeForPharma - April 14, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Digital Content opportunities
Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercialImage: URL: https://eloqua.eyeforpharma.com/LP=27091?extsource=efp_websiteExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - April 13, 2020 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
From reactive to predictive: Concerto ’s new compositions
In his 2016 book Healthcare Disrupted, Dr Jeff Elton sketched out how healthcare would move from being reactive to proactive thanks to the ubiquity of electronic health records (EHRs) and other datasets. That future is now upon us, says Elton, CEO of precision oncology business Concerto HealthAI. whose mission is to combine RWE and AI to drive better insights and patient outcomes. The firm, which recently raised $150m to invest in growing ‘next-generation’ clinical research, is now busy putting technologies and tools into hundreds of life science companies and clinical settings to ask questions of real-world data r...
Source: EyeForPharma - April 10, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Moving remote: the post-pandemic clinical trial
The restrictions on movement and normal interaction owing to COVID-19 pose a distinct challenge to the traditional clinical trial model, as patients, investigators and clinical staff are either confined to their homes or seeking to avoid healthcare settings.
Those running clinical trials over the past weeks have had to adapt rapidly by fast-tracking digital capabilities to ensure continued delivery. With the future of existing trials hanging in the balance, some have been pivoting to remote delivery – sometimes in the space of under a week.
Speaking at eyeforpharma Virtual, a digital version of the Barcelona e...
Source: EyeForPharma - April 3, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news
